Skip to content
Axcess News – Lifestyle
Author:
NRx Pharmaceuticals, Inc.
NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression
September 30, 2026
NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine
September 15, 2026
First Interventional Psychiatry Use of FDA-Cleared Zeta TMS AI Driven Robotic System in Treatment of Suicidal Bipolar Depression by NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
September 14, 2026
GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS)
September 14, 2026
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical’s FDA-Cleared Robotic TMS System
September 11, 2026
NRx Pharmaceuticals to Present at Investor Conferences
September 8, 2026
Mitsubishi Motors Strengthens Future of the Brand in the United States Through Updated Momentum 2030 Plan
August 29, 2026
FDA First Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies Noted for Suicidal Bipolar Depression Treatment from NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
August 27, 2026
NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications
April 15, 2026
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress
March 24, 2026